Literature DB >> 34662871

Case Report: Rapid Response to Low-Dose Thalidomide in a Case of Severe Steroid Recalcitrant Erythema Nodosum Leprosum.

Bathula Savitha, Kabir Sardana, Ritu Kumari, Ananta Khurana, Surabhi Sinha, Soumya Sachdeva.   

Abstract

Erythema nodosum leprosum (ENL), or type 2 lepra reaction, presents with crops of evanescent, tender erythematous nodules accompanied by fever, arthralgia, malaise and organ-specific manifestations and is seen in borderline and lepromatous leprosy. The drugs approved for ENL include nonsteroidal anti-inflammatory drugs, systemic steroids, thalidomide and clofazimine. The management of ENL is challenging because long-term steroid use leads to steroid dependence. The present patient had severe steroid recalcitrant ENL with vesicular and pustular lesions mimicking Sweet's syndrome and was treated effectively with a low-dose thalidomide regimen (100 mg/d) as opposed to high dose (400 mg/d) recommended in literature. We discuss the patho-mechanics and clinical utility of a low-dose thalidomide regimen as an effective treatment option for ENL.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34662871      PMCID: PMC8733501          DOI: 10.4269/ajtmh.21-0683

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   3.707


  14 in total

1.  Neutrophils isolated from leprosy patients release TNF-alpha and exhibit accelerated apoptosis in vitro.

Authors:  R B Oliveira; M O Moraes; E B Oliveira; E N Sarno; J A Nery; E P Sampaio
Journal:  J Leukoc Biol       Date:  1999-03       Impact factor: 4.962

2.  Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation.

Authors:  Patrick A J Haslett; Paul Roche; C Ruth Butlin; Murdo Macdonald; Niraj Shrestha; Rakesh Manandhar; Joe Lemaster; Rachel Hawksworth; Mahesh Shah; A Steven Lubinsky; Matthew Albert; Jason Worley; Gilla Kaplan
Journal:  J Infect Dis       Date:  2005-11-10       Impact factor: 5.226

Review 3.  Thalidomide as an immunotherapeutic agent: the effects on neutrophil-mediated inflammation.

Authors:  Kozo Yasui; Norimoto Kobayashi; Takashi Yamazaki; Kazunaga Agematsu
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

4.  Erythema Nodosum Leprosum Neutrophil Subset Expressing IL-10R1 Transmigrates into Skin Lesions and Responds to IL-10.

Authors:  Fabiana Santos Pacheco; Rhana Berto da Silva Prata; Sheila Santos Brandão; Helen Ferreira; Thaís Fernanda Rodrigues; Jéssica Brandão Dos Santos; Camila Oliveira da Silva; Isabella Forasteiro Tavares; Mayara Abud Mendes; Ana Carolina Duarte Pereira Rodrigues; Alice de Miranda Machado; José Augusto da Costa Nery; Thaís Porto Amadeu; Milton Ozório Moraes; Euzenir Nunes Sarno; Veronica Schmitz
Journal:  Immunohorizons       Date:  2020-02-07

5.  A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum.

Authors:  Laarni G Villahermosa; Tranquilino T Fajardo; Rodolfo M Abalos; Maria V Balagon; Esterlina V Tan; Roland V Cellona; Jeffrey P Palmer; Janet Wittes; Steven D Thomas; Karin A Kook; Gerald P Walsh; Douglas S Walsh
Journal:  Am J Trop Med Hyg       Date:  2005-05       Impact factor: 2.345

6.  Thalidomide suppressed IL-1beta while enhancing TNF-alpha and IL-10, when cells in whole blood were stimulated with lipopolysaccharide.

Authors:  Edward Shannon; Robert Noveck; Felipe Sandoval; Burde Kamath
Journal:  Immunopharmacol Immunotoxicol       Date:  2008       Impact factor: 2.730

7.  The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum.

Authors:  E P Sampaio; G Kaplan; A Miranda; J A Nery; C P Miguel; S M Viana; E N Sarno
Journal:  J Infect Dis       Date:  1993-08       Impact factor: 5.226

Review 8.  The role of thalidomide in the management of erythema nodosum leprosum.

Authors:  Steven L Walker; Michael F R Waters; Diana N J Lockwood
Journal:  Lepr Rev       Date:  2007-09       Impact factor: 0.537

Review 9.  Thalidomide in the treatment of leprosy.

Authors:  Steve K Teo; Ken E Resztak; Michael A Scheffler; Karin A Kook; Jerry B Zeldis; David I Stirling; Steve D Thomas
Journal:  Microbes Infect       Date:  2002-09       Impact factor: 2.700

10.  Thalidomide in the treatment of erythema nodosum leprosum (ENL) in an outpatient setting: A five-year retrospective analysis from a leprosy referral centre in India.

Authors:  Brahmaiah Upputuri; Michael Sukumar Pallapati; Patrick Tarwater; Aparna Srikantam
Journal:  PLoS Negl Trop Dis       Date:  2020-10-09
View more
  1 in total

Review 1.  New Practical Aspects of Sweet Syndrome.

Authors:  Tejas P Joshi; Sarah K Friske; David A Hsiou; Madeleine Duvic
Journal:  Am J Clin Dermatol       Date:  2022-02-14       Impact factor: 7.403

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.